Stock Updates

Is this Large Market Cap Stock target price reasonable for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)?

The company in question is, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) currently with a stock price of 47.85 (-5.66% today). The market cap for Agios Pharmaceuticals, Inc. is 2143.93, and is in the sector Healthcare, and Biotechnology industry. The target price for Agios Pharmaceuticals, Inc. is 63.17. Currently Agios Pharmaceuticals, Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for Agios Pharmaceuticals, Inc. is 666.62 and so far today it is 332070.

Performance in the last year for Agios Pharmaceuticals, Inc. has been -28.69%. For EPS growth, Agios Pharmaceuticals, Inc. has seen a growth of -97.90%, and is looking to grow in the next year to -5.20%. More long term stats show that EPS growth has been *TBA over the last five years and could be *TBA for the next five years. Agios Pharmaceuticals, Inc. has seen sales growth quarter over quarter at -83.80%, with EPS growth quarter over quarter at *TBA. The 20-day simple moving average is 5.23%, with the 200-day simple moving average coming to 4.45%.

Since the IPO date for Agios Pharmaceuticals, Inc. on the 7/24/2013, Agios Pharmaceuticals, Inc. has seen performance year to date to be -21.87%. With Agios Pharmaceuticals, Inc. trading at 47.85, the dividend yield is *TBA, and the EPS is -4.24.

So could Agios Pharmaceuticals, Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 42.88 and the P/B is at 5.06. The P/cash is 2.82, with P/free cash flow at *TBA.

Agios Pharmaceuticals, Inc. ability to deal with debt shows that the current ratio is 7.5, and the quick ratio is 7.5. This is with long term debt/equity at 0, and total debt/equity at 0.

In terms of margins, Agios Pharmaceuticals, Inc. has a gross margin of *TBA, an operating margin of *TBA and a profit margin of *TBA.Payout ratio for Agios Pharmaceuticals, Inc. is *TBA. Return on assets come to *TBA with return on investment coming to -34.40%.

Insider ownership for Agios Pharmaceuticals, Inc., is at 0.40% and institutional ownership comes to 86.50%. Outstanding shares are at 42.27. While shares float is 40.4. The float short is currently 14.85%, and short ratio is 9.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment